Penumbra has shown significant operating leverage and profitability, with strong topline growth. Find out my recommendation ...

Global Expansion Continues: Penumbra derives a significant portion of its revenues internationally. The company expects to materially increase revenues and profitability in its international business ...

BTIG analyst Ryan Zimmerman maintained a Buy rating on Penumbra (PEN – Research Report) yesterday and set a price target of $270.00. The ...

After hours: January 13 at 6:10:32 PM EST Loading Chart for PEN ...

After the MedTech giant Stryker (NYSE:SYK) agreed to offer $4.9B in cash to acquire Inari Medical (NASDAQ:NARI), a maker of ...

Penumbra is demonstrating strong growth within the company’s Thrombectomy business, banking on the rapid increase in sales of the company’s vascular thrombectomy products in the United States ...

Irrespective of market conditions, companies with favorable efficiency levels are more likely to be investors’ choices.The reason is that a company with a favorable efficiency level is expected to ...

In a report released on January 6, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Penumbra (PEN – Research Report), with a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Director Harpreet Grewal sold 167 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $241.28, for a total value of $40,293.76. Following ...